» Articles » PMID: 432544

Plasma Enteroglucagon After Jejunoileal Bypass with 3:1 or 1:3 Jejunoileal Ratio

Overview
Publisher Informa Healthcare
Specialty Gastroenterology
Date 1979 Jan 1
PMID 432544
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Enteroglucagon concentration in peripheral blood was determined before and after a test meal in 24 morbidly obese patients. Eighteen had jejunoileal bypass, 6 with a 3:1 and 12 with a 1:3 jejunoileal ratio of the functioning segment, and 6 were unoperated. All three groups exhibited an increment of enteroglucagon concentration after the meal. Both the fasting values and the postprandial integrated increments were higher in operated patients than in unoperated patients and higher after 1:3 bypass than after 3:1 bypass. The findings agree with the hypothesis that enteroglucagon secretion is stimulated by exposure of the lower bowel to upper-bowel content, and that the effect of enteroglucagon is, as seen after bypass operation, stimulation of growth and reduction of motility of the intestine.

Citing Articles

Striking the Balance: GLP-1/Glucagon Co-Agonism as a Treatment Strategy for Obesity.

Hope D, Vincent M, Tan T Front Endocrinol (Lausanne). 2021; 12:735019.

PMID: 34566894 PMC: 8457634. DOI: 10.3389/fendo.2021.735019.


Mechanisms in bariatric surgery: Gut hormones, diabetes resolution, and weight loss.

Holst J, Madsbad S, Bojsen-Moller K, Svane M, Jorgensen N, Dirksen C Surg Obes Relat Dis. 2018; 14(5):708-714.

PMID: 29776493 PMC: 5974695. DOI: 10.1016/j.soard.2018.03.003.


Glucagon-like peptide 1 in the pathophysiology and pharmacotherapy of clinical obesity.

Anandhakrishnan A, Korbonits M World J Diabetes. 2016; 7(20):572-598.

PMID: 28031776 PMC: 5155232. DOI: 10.4239/wjd.v7.i20.572.


The physiology underlying Roux-en-Y gastric bypass: a status report.

Lutz T, Bueter M Am J Physiol Regul Integr Comp Physiol. 2014; 307(11):R1275-91.

PMID: 25253084 PMC: 4315446. DOI: 10.1152/ajpregu.00185.2014.


Action and therapeutic potential of oxyntomodulin.

Pocai A Mol Metab. 2014; 3(3):241-51.

PMID: 24749050 PMC: 3986661. DOI: 10.1016/j.molmet.2013.12.001.